#1 Clinical Trials Search in Europe

Teclistamab

Teclistamab is an innovative drug being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer. This article explores the ongoing research into teclistamab’s safety and effectiveness in patients with relapsed or refractory multiple myeloma who have exhausted other treatment options.

Table of Contents

What is Teclistamab?

Teclistamab is a new and promising medication being studied for the treatment of certain blood cancers. It’s also known by other names such as JNJ-64007957 and Tecvayli[1]. Teclistamab is a type of drug called a bispecific antibody, which means it’s designed to target two specific proteins at the same time[2].

What Conditions Does Teclistamab Treat?

Teclistamab is primarily being studied for the treatment of two main conditions:

  • Multiple Myeloma: This is a type of blood cancer that affects plasma cells, which are a type of white blood cell[1].
  • AL Amyloidosis: This is a rare disease where abnormal proteins build up in organs, causing them to malfunction[3].

Most of the clinical trials are focusing on patients with relapsed or refractory multiple myeloma, which means their cancer has either come back after treatment or hasn’t responded well to other treatments[4].

How Does Teclistamab Work?

Teclistamab works in a unique way. It’s designed to bind to two different proteins:

  1. BCMA (B-cell maturation antigen): This is found on the surface of myeloma cells.
  2. CD3: This is found on T-cells, which are a type of immune cell that can fight cancer.

By binding to both of these proteins, Teclistamab helps bring the cancer cells and the T-cells together. This allows the T-cells to recognize and attack the cancer cells more effectively[2].

How is Teclistamab Administered?

Teclistamab is typically given as a subcutaneous injection, which means it’s injected just under the skin[3]. The dosing schedule often includes:

  • Initial “step-up” doses to help the body adjust to the medication
  • Regular weekly doses thereafter

For example, one study used the following dosing schedule: 0.06 mg/kg on day 1, 0.3 mg/kg on day 4, 1.5 mg/kg on day 8, and then 1.5 mg/kg weekly[5].

Teclistamab in Clinical Trials

Teclistamab is being studied in various clinical trials to determine its effectiveness and safety. These trials include:

  • Phase 1 trials: These early studies focus on finding the right dose and understanding how the drug works in the body[2].
  • Phase 2 trials: These studies look more closely at how well the drug works for specific conditions[6].
  • Phase 3 trials: These larger studies compare Teclistamab to existing treatments or combinations of treatments[7].

Efficacy of Teclistamab

Early results from clinical trials suggest that Teclistamab may be effective in treating multiple myeloma and AL amyloidosis. Researchers are looking at several measures to determine how well the drug works:

  • Overall Response Rate (ORR): This measures how many patients see their cancer shrink or disappear[6].
  • Complete Response (CR) Rate: This looks at how many patients have no detectable cancer after treatment[3].
  • Minimal Residual Disease (MRD) Negativity: This very sensitive test checks for any remaining cancer cells[5].
  • Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse[7].

Safety and Side Effects

As with all medications, Teclistamab can cause side effects. Researchers are carefully monitoring patients for:

  • Cytokine Release Syndrome (CRS): This is a condition where the immune system becomes overactive, causing fever and other symptoms[1].
  • Neurological side effects: These could include confusion or difficulty speaking[1].
  • Blood-related side effects: Such as low blood cell counts[1].
  • Infections: Patients may be at higher risk of developing infections[1].

The severity and frequency of these side effects are being closely monitored in clinical trials[8].

Impact on Quality of Life

Researchers are not only interested in how well Teclistamab fights cancer, but also in how it affects patients’ overall well-being. Several studies are using questionnaires to assess:

  • Physical functioning
  • Emotional well-being
  • Ability to perform daily activities
  • Pain levels
  • Fatigue

These assessments help doctors understand how the treatment impacts patients’ day-to-day lives[7].

Aspect Details
Drug Name Teclistamab (also known as JNJ-64007957, Tecvayli)
Type of Drug Bispecific antibody targeting BCMA and CD3
Primary Indication Relapsed or refractory multiple myeloma
Administration Method Primarily subcutaneous injection, some studies with intravenous infusion
Key Outcomes Measured Overall response rate, progression-free survival, overall survival, minimal residual disease negative rate
Safety Monitoring Adverse events, serious adverse events, laboratory abnormalities
Quality of Life Assessments EORTC QLQ-C30, EQ-5D-5L, Patient Global Impression of Severity (PGIS)
Trial Phases Phase 1, Phase 2, and expanded access programs

FAQ

  • What is teclistamab? Teclistamab is a bispecific antibody that targets both BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T-cells. It's designed to redirect T-cells to attack myeloma cells.
  • What types of multiple myeloma is teclistamab being studied for? Teclistamab is primarily being studied in clinical trials for relapsed or refractory multiple myeloma, which means the cancer has returned after treatment or is not responding to current treatments.
  • How is teclistamab administered? Teclistamab is typically administered through subcutaneous (under the skin) injection, though some trials have also studied intravenous administration.
  • What are some potential side effects of teclistamab? Common side effects may include cytokine release syndrome, infections, and changes in blood cell counts. The severity and frequency of side effects are being closely monitored in clinical trials.
  • How effective has teclistamab been in clinical trials? Early clinical trial results have shown promising overall response rates in patients with relapsed or refractory multiple myeloma. However, more research is needed to fully understand its long-term effectiveness and safety.

Ongoing Clinical Trials on Teclistamab

  • JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

    Recruiting

    3 1 1
    Investigated drugs:
    France Germany Greece Italy The Netherlands Norway +1

  • Study of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.

    Recruiting

    2 1 1 1
    Investigated drugs:
    Sweden

  • Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy The Netherlands Norway Spain

  • Study on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study of Teclistamab for Patients with Previously Treated AL Amyloidosis

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Greece Italy The Netherlands

  • Study of Teclistamab with Daratumumab or Lenalidomide for Elderly Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8

  • Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy The Netherlands

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • Relapsed Multiple Myeloma: Multiple myeloma that has returned after a period of improvement following treatment.
  • Refractory Multiple Myeloma: Multiple myeloma that does not respond to or stops responding to treatment.
  • Bispecific Antibody: A type of engineered antibody that can bind to two different targets at the same time.
  • BCMA (B-cell maturation antigen): A protein found on the surface of myeloma cells and some healthy B cells.
  • CD3: A protein complex found on the surface of T cells, which are important immune cells.
  • Cytokine Release Syndrome (CRS): A condition that can occur as a side effect of some cancer treatments, causing symptoms like fever, nausea, and difficulty breathing.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Subcutaneous (SC) Injection: A method of administering medication by injecting it under the skin.
  • Intravenous (IV) Infusion: A method of administering medication directly into a vein.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.

References

  1. https://clinicaltrials.gov/study/NCT06477783
  2. https://clinicaltrials.gov/study/NCT03145181
  3. https://clinicaltrials.eu/trial/study-of-teclistamab-for-patients-with-previously-treated-al-amyloidosis/
  4. https://clinicaltrials.gov/study/NCT06425991
  5. https://clinicaltrials.gov/study/NCT06699394
  6. https://clinicaltrials.gov/study/NCT04557098
  7. https://clinicaltrials.eu/trial/study-of-teclistamab-and-lenalidomide-for-maintenance-therapy-in-patients-with-newly-diagnosed-multiple-myeloma-after-stem-cell-transplant/
  8. https://clinicaltrials.gov/study/NCT04696809